A population framework for predicting the proportion of people infected by the far-field airborne transmission of SARS-CoV-2 indoors

Christopher Iddon^a, Benjamin Jones^{a,*}, Patrick Sharpe^a, Muge Cevik^b, Shaun Fitzgerald^c

^aDepartment of Architecture and Built Environment, University of Nottingham, Nottingham, UK ^bDepartment of Infection and Global Health, School of Medicine, University of St Andrews, St Andrews, UK ^cDepartment of Engineering, Cambridge University, Cambridge, UK

Abstract

The number of occupants in a space influences the risk of far-field airborne transmission of SARS-CoV-2 because the likelihood of having infectious and susceptible people both correlate with the number of occupants. This paper explores the relationship between occupancy and the probability of infection, and how this affects an individual person and a population of people. Massbalance and dose-response models determine far-field transmission risks for an individual person and a population of people after sub-dividing a large *reference* space into 10 identical *comparator* spaces.

For a single infected person when the *per capita* ventilation rate is preserved, the viral dose received by an individual person in the *comparator* space is 10-times higher because the equivalent ventilation rate per infected person is lower.

Preprint submitted to Indoor Air

December 3, 2021

^{*}Corresponding author Email address: benjamin.jones@nottingham.ac.uk (Benjamin Jones)

> However, accounting for population dispersion, such as the community prevalence, the probability of an infected person being present and uncertainty in their viral load, shows the probability of transmission increases with occupancy level. Also, far-field transmission is likely to be a rare event that requires a set of Goldilocks conditions that are *just right*, when mitigation measures have limited effect.

> Therefore, resilient buildings should deliver the equivalent ventilation rate required by standards and increase the space volume per person, but also require reductions in the viral loads and the infection rate of the wider population.

> *Keywords:* relative exposure index, ventilation, aerosols, transmission risk, viral load, COVID-19

1 Nomenclature

- $_{2}$ \bar{I} mean number of infected people present
- $_{3}$ \overline{D} mean dose in a space where one infected personis present
- $_{4}$ \overline{I} mean number of infected people in a space that contains a potential transmission event
- ⁶ $\overline{P(R)_I}$ mean individual probability of infection occurring in a scenario
- 7 $\overline{P(R)}$ mean individual infection risk that occurs in all potential transmission 8 scenarios
- 9 ϕ total removal rate (s⁻¹)
- $_{10}$ C community infections rate (%)
- D D dose (viable virions)
- ¹² G emission rate of RNA copies (RNA copies s⁻¹)
- $_{13}$ I number of infected people
- $_{14}$ K fraction of aerosol particles absorbed by respiratory tract
- $_{15}$ k reciprocal of the probability that a single pathogen initiates an infection
- $_{17}$ L viral load (RNA copies per ml of respiratory fluid)
- $_{18}$ N number of occupants
- ¹⁹ N_s number of susceptible people exposed

- $_{20}$ $N_s(I)$ number of susceptible people exposed in spaces that contain I infected
- 21 people
- $_{22}$ N_t number of transmissions in the entire population
- ²³ $N_t(I)$ number of transmissions that occur in spaces that contain I infected ²⁴ people
- $_{25}$ N_{pop} population size
- ²⁶ P(0 < I < N) probability of a space containing a potential transmission
- $_{27}$ P(I) probability of I infected people present
- ²⁸ P(L) probability of a viral load
- ²⁹ P(R) individual probability of infection
- P(S) probability of a person being both susceptible and exposed to the virus
- q_{sus} susceptible person respiratory rate (m³ s⁻¹)
- $_{32}$ T exposure period (s)
- $_{33}$ V space volume (m³)

 $_{34}$ v viable fraction

35 1. Introduction

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel virus that causes COVID-19. In 2020, it spread rapidly worldwide

causing a pandemic. The transmission of the virus occurs when it is encap-38 sulated within respiratory droplets and aerosols and inhaled by a susceptible 30 person [1]. These are most concentrated in the exhaled puff of an infected 40 person, which includes a continuum of aerosols and droplets of all sizes as a 41 multiphase turbulent gas cloud [2, 3]. The subsequent transport of infectious 42 aerosols from the exhaled puff occurs differently in outdoor and indoor en-43 vironments. Outside, air movement disrupts the exhaled puff, a prodigious 44 space volume rapidly dilutes it [4], and ultra-violet (UV) light renders the 45 virus biologically non-viable over a short period of time [5]. Inside, the mag-46 nitude of air movement is usually insufficient to disrupt the exhaled puff, a 47 finite space volume and lower ventilation rates concentrate aerosols in the air, 48 and there is usually less UV light [6]. Accordingly, transmission of the virus 49 occurs indoors more frequently than outdoors [7, 8], and inhaling the exhaled 50 puff at close contact is more likely to lead to an infective dose than when 51 inhaling indoor air at a distance where the virion laden aerosols are diluted. 52 This is consistent with the epidemiological understanding that SARS-CoV-2 53 is spread primarily by close contact where it might be possible to smell a 54 person's coffee breath [2, 3, 9, 10, 11]. However, it is still possible for a sus-55 ceptible person to inhale an infective dose of aerosol borne virus, from shared 56 indoor air, known as *far-field* airborne transmission, and occurs at distances 57 of $> 2 \,\mathrm{m}$. Far-field transmission is linked to several super spreading events 58 and is often correlated with poor indoor ventilation, long exposure times, 59 and respiratory activities that increase aerosol and viral emission, such as 60 singing [12, 13, 14]. 61

62

The number of occupants in a space can have an influence on the risk of

airborne transmission because the likelihood of having infectious and suscep-63 tible people both scale with the number of occupants. Therefore, it may be 64 advantageous to sub-divide a large space into a number of identical smaller 65 spaces to reduce the transmission risk. Here, the space volume and ventila-66 tion rate per person is kept constant, and occupants are divided into smaller 67 groups of people. The impact of this strategy on virus transmission is not 68 obvious. On one hand, the lower occupancy space reduces the probability of 69 an infected person being present, and also reduces the number of susceptible 70 people who are exposed to infected people. On the other hand, the ventilation 71 rate per infected person is likely to be smaller in the smaller space, increasing 72 the transmission risk for any susceptible people present. Accordingly, this 73 paper explores the relationship between occupancy and the probability of in-74 fection, and how this affects an individual person and a population of people. 75 We take a theoretical approach to consider the infection risk for the popula-76 tion of a large space and compare it to the same population distributed in a 77 number of smaller identical spaces. 78

We first consider the infection risk for a person using an existing analytical model [15] to predict the dose and the probability that the dose leads to infection. We then consider the infection risk for two equal populations distributed evenly in either the big space or a number of smaller spaces, by considering the community infection rate and the probability of infection from a viral dose.

Section 2 outlines the modelling approach and the input data. Section 3
considers the personal risks from sub-division and Section 4 considers the
risks for a population. Section 5 discusses factors that affect infection risk

⁸⁸ and limitation of the work.

⁸⁹ 2. Theoretical approach

An analytical model is used to predict the dose of viral genome copies of an individual person and associated individual and population infection risks of infection.

93 2.1. Dose and infection risk

The mass-balance model of Jones *et al.* [15] is used to predict the number of RNA copies absorbed by the respiratory tract of a person exposed to aerosols in well mixed air over a significant period of time and combined with the viable fraction, v, to give a dose, D.

$$D \simeq \frac{K q_{sus} G T v}{\phi V} \tag{1}$$

Here, K is the fraction of aerosol particles absorbed by respiratory tract, 98 q_{sus} is the respiratory rate (m³ s⁻¹), G is the emission rate of RNA copies 99 $(RNA copies s^{-1})$ and is a function of the respiratory activity (see Jones et 100 al.), T is the exposure period (s), ϕ is the total removal rate (s⁻¹), which 101 represents the sum of all removal by ventilation, surface deposition, biological 102 decay, respiratory tract absorption, and filtration, and V is the space volume 103 (m³). The product ϕV can be considered to be an *equivalent* ventilation 104 rate. The approach is common and has been used by others to investigate 105 exposure in well mixed air [16, 17]. 106

¹⁰⁷ For a full description of the model, a discussion of uncertainty in suitable ¹⁰⁸ inputs, and a sensitivity analysis see Jones *et al.* [15]. The analysis shows that

the most sensitive parameter is G, the rate of emission of RNA copies. G is a 109 function of the *viral load* in the respiratory fluid, L (RNA copies per ml) and 110 the volume of aerosols emitted, which in turn is a function of exhaled breath 111 rate and respiratory activity; see Appendix Appendix A. The distribution 112 of the viral load within the infected population is reported to be log-normal 113 by Yang et al. [4], Weibull by Chen et al. [18], and Gamma by Ke et al. [19]. 114 This suggests that the true distribution is unknown and so we assume that 115 it is log-normally distributed with a mode of 10⁷ RNA copies per ml using the 116 data of Chen et al. [20]; see Table 2 and Figure 1. We explore variations in 117 these values in Section 2.3 and discuss their origin and uncertainty in them 118 in Section 5.5. The probability of a viral load, P(L), can then be determined 119 using the standard equation for the log-normal probability distribution func-120 tion. 121

The dose can be used to estimate a probability of infection using a doseresponse curve. However, there is no dose-response curve for SARS-CoV-2. A number of studies [21, 16, 22] apply a dose curve for the SARS-CoV-1 virus, which is a typical dose curve for corona viruses, and so it is applied here. There are obvious problems with this extrapolation and they are discussed in Section 5.5. The probability of infection of an individual person, P(R), is given by

$$P(R) = 1 - e^{-D/k}$$
(2)

where, k is the reciprocal of the probability that a single pathogen initiates an infection. We use a value of k = 410 following DeDiego *et al.*[23].

131 2.2. Individual risk

A Relative Exposure Index (REI) is used to compare exposure risk for an individual person between two spaces following Jones *et al.* [15]. This approach has already been used to inform national policy on the role of ventilation in controlling SARS-CoV-2 transmission and to identify the appropriate application of air cleaning devices [24, 25].

The REI is the ratio of the dose, D, received by a susceptible occupant 137 in each of two spaces using Equation 1 where the *reference* space is the 138 denominator and the *comparator* space is the numerator. An advantage 130 of using an REI is that uncertainty in the viral load of respiratory fluid 140 (RNA copies per ml), which is used to determine the viral emission rate, G141 $(RNA \text{ copies } m^{-3})$, and the unknown dose response, cancel allowing scenarios 142 to be compared. When the REI is > 1 the comparator space is predicted to 143 pose a greater risk to an individual susceptible occupant because they inhale 144 a larger dose in the comparator scenario, although the absolute risk that this 145 dose will lead to a probability of infection is not considered. Any space that 146 wishes to have a REI of unity or less, must at least balance the parameters 147 in Equation 1. 148

149 2.3. Population infection risk

A limitation of the REI is that it does not consider the probability of encountering an infected person with the same viral load in each scenario. The probability that a number of infected people, I, is present in a space, P(I), with a number of people present, N, is determined by considering the

 $_{154}$ community infections rate, C, and standard number theory for combinations.

$$P(I) = \frac{C^{I}(1-C)^{(N-I)}N!}{I!(N-I)!}$$
(3)

The total number of transmissions that occur in a population, N_t , of N_{pop} people, is the sum of the number of transmissions that occur in each transmission scenario.

$$N_t = \sum_{I=1}^{N-1} N_t(I)$$
 (4)

For a large population, the number of people infected in each space can be given by the product of the number of susceptible people exposed, N_s , and the mean individual probability of infection for a scenario, $\overline{P(R)_I}$.

$$N_t = \sum_{I=1}^{N-1} N_s(I) \overline{P(R)_I} \tag{5}$$

$$N_s(I) = P(I)\frac{N_{pop}}{N}(N-I)$$
(6)

where $N_s(I)$ denotes the number of susceptible people exposed in spaces that contain I infected people, P(I) is the probability that a space contains I infected people, and $N_{pop} N^{-1}$ denotes the total number of spaces that occur when a population N_{pop} is divided into groups of N people. Here, the proportion of the population who are infected can be given by

$$PPI = \frac{N_t}{N_{pop}} = \sum_{I=1}^{N-1} P(I) \frac{N-I}{N} \overline{P(R)_I}$$
(7)

The exact solution for Equation 7 becomes increasingly difficult to evaluate as the space size increases. The calculation complexity is unlikely to be justified given the uncertainties in both the modelling assumptions and the available data. Therefore, simple approximations to the equation are desirable.

One approach is to express the number of transmission events using a single mean individual risk for all possible transmission scenarios. Here, the *PPI* can be expressed as

$$PPI = P(S)\overline{P(R)} \tag{8}$$

where P(S) is the proportion of the population who are both exposed and susceptible, and $\overline{P(R)}$ is the average individual infection risk that occurs in all potential transmission scenarios.

Transmission events can only occur when there are both one or more infected people present in a space (I > 0) and one or more susceptible people are present (I < N). It follows that the probability of a space containing a potential transmission event is given by

$$P(0 < I < N) = 1 - C^{N} - (1 - C)^{N}$$
(9)

As the number of occupants tends to infinity, the probability that the space contains a potential transmission event approaches one, and is equal to zero for single occupancy spaces. This suggests that it may be better to partition a large space; see Section 1. Likewise, the probability that a space contains susceptible people can be minimised by reducing the community infections

rate, as long as the community infections rate is less than half. Furthermore, each space contains (N - I) susceptible people in it. This allows the probability that a user of the space is both susceptible and exposed to be given by

$$P(S) = (1 - C) - (1 - C)^{N}$$
(10)

where P(S) approaches the proportion of susceptible people in the wider community as $N \to \infty$.

Evaluating the mean individual risk is non-trivial. Here an approximation is used, where

$$\overline{P(R)} = \int_{1}^{\infty} P(L) \left(1 - e^{-\frac{D}{k}\overline{I}}\right) dL \tag{11}$$

Here P(L) is the probability of a person having a viral load L, and \overline{I} denotes the mean number of infected people in a space that contains a potential transmission event, and is given by

$$\bar{I} = \frac{N\left(C - C^N\right)}{P(0 < I < N)} \tag{12}$$

¹⁹⁷ This allows the proportion of people infected in a scenario to be approximated¹⁹⁸ by

$$PPI \approx P(S) \int_{1}^{\infty} P(L) \left(1 - e^{-\frac{D}{k}\overline{I}}\right) dL$$
(13)

¹⁹⁹ and is further simplified by assuming that mean infection probabilities are

adequately described using a mean viral load, which can often be found
 directly from the literature. Here

$$PPI \approx P(S) \left(1 - e^{-\frac{\overline{D}}{k}\overline{I}} \right)$$
(14)

where \overline{D} is the mean dose received in the space where one infected person is present.

204 2.4. Scenarios

The probabilities given in Section 2.3 can be used to consider how the 205 number of occupants may affect the relative exposure risk at population scale. 206 First, we define a reference space against which others are compared. This 207 space is an office, which is chosen because it is a common space that is well 208 regulated in most countries and has consistent occupancy densities. It has 209 an occupancy density of $10 \,\mathrm{m}^2$ per person, a floor to ceiling height of $3 \,\mathrm{m}$, 210 and an outdoor airflow rate of $101s^{-1}$ per person. There are 50 occupants 211 who are assumed to be continuously present for 8 hours breathing for 75%212 and talking for 25%. Hereon it is known as the Big Office. 213

Then, we define a comparator space by subdividing the 50 person office into 10 identical spaces. Each space preserves the occupancy density, the *per capita* space volume, the outdoor airflow rate per person, and the air change rate. Hereon each comparator space is known as the Small Office.

All scenario inputs are given in Table 1.

219 2.5. Probabilistic estimates

To investigate overdispersion in the model we use a Monte Carlo approach that selects ten populations of 0.5×10^6 people and divides them into an equal

	Big Office	Small Office
	Reference	Comparator
Number of occupants, N	50	5
Space Volume, $V (m^3)$	1500	150
Per capita volume, $V N^{-1}$ (m ³ per person)	30	
Air flow rate, $\psi V (ls^{-1})$	500	50
Air change rate, ψ (h ⁻¹)	1.2	
Removal rate, ϕ (h ⁻¹)	2.26	
Equivalent ventilation rate , $\phi V (l s^{-1})$	942	94.2
Exposure time, T (h)	8	
Dose constant, k [23]	410	
Viable fraction, v (%)	100	
Viral load (RNA copies per ml) [20]	10^{7}	
Respiratory activity, breathing:talking (%)	72:25	
Viral emission rate, G (RNA copies per hour)	394	
Respiratory rate, q_{sus} (m ³ h ⁻¹)	0.56	
Community infection rate, C	1:100	
Dose, D (viable virions inhaled)	0.245	2.450
REI	1	10

All values converted to SI units before application.

number of spaces, depending on the scenario; see Section 2.4. The predictions
confirm the mathematics described herein, and identify the uncertainty in the
number of transmissions that occur for each scenario; see Section 5.4. All
inputs are given in Tables 1 and 2.

We do not explore uncertainty in other inputs because this has been done before [15] and to limit the exploration of uncertainty in the viral load and the community infection rate.

	Big Office	Small Office	
	Reference	Comparator	
Viral load [20]			
(RNA copies per ml)	$LN(2.1 \times 10^9, 2.0 \times 10^{10})$		
P(R) (%)	0.062	0.620	
$P(I=0) \ (\%)$	61	95	
$P(0 < I < N) \ (\%)$	39	5	
\bar{I}	1.27	1.02	
P(S) (%)	39	5	
$PPI \ (\%)$	1.59	0.43	
TR	0.27		

Table 2: Scenario inputs and calculations of population risk.

LN, log-normal(μ, σ)

All values converted to SI units before application.

229 3. Individual risk

The REI is the ratio of the dose predicted using Equation 1 for Big Office 230 and Small Office; see Section 2.2. When the number of infected people and 231 their respiratory activities, and the breathing rates of susceptible occupants, 232 are identical in each space, the REI simplifies to a ratio of equivalent ven-233 tilation rates, ϕV . The equivalent ventilation rate is used to determine the 234 steady state concentration of viable virions. Table 1 shows that the removal 235 rate ϕ is identical in both spaces and so the REI becomes a simple ratio 236 of the number of occupants. This suggests that, in the presence of a single 237 infected person, the relative risk is 10 times higher in the Small Office. This 238 occurs because the Small Office contains ten times fewer people than the Big 230 Office, and therefore the ventilation rate *per infector* is ten times smaller. 240

The equivalent ventilation rate per person, $\phi V N^{-1}$, is identical in both spaces and, if it is desirable to preserve the equivalent ventilation per person

²⁴³ in two different spaces, the space volume per person must be preserved.

The removal rate, ϕ , includes the biological decay of the virus and the deposition of aerosols onto surfaces. Both of these removal mechanisms are space-volume dependent, and so their contribution to the removal of the virus is greater in spaces with a larger volume. Therefore, increasing the space volume per person also has the effect of reducing the REI. This has obvious physical limitations and a simpler approach is to reduce the number of people per unit of volume.

Equation 1 is used to calculate the dose of viable virions in each space 251 and Table 1 shows that the magnitudes of the doses are small. There is great 252 uncertainty in these values, attributable to modelling assumptions and in the 253 inputs given in Table 1, but an increase of an order of magnitude still leads 254 to a small dose. This fact is compounded by the value of unity for the viable 255 fraction, which has the effect that all RNA copies inhaled are viable, which 256 is unlikely. A viable fraction of unity was chosen because its true value is 257 currently unknown, and this assumption simplifies the analysis. The value 258 is clearly likely to be $\ll 100\%$ in reality, and so the actual doses would be 259 substantially lower than those estimated here. This suggests that far-field 260 transmission in buildings requires high viral emission rates, G, which are 261 likely to be a rare event. 262

The probability of an infection occurring when a susceptible occupant is exposed to the dose reported in Table 1 is estimated using Equation 2 to be P(R) < 1% for both spaces and is approximately 10 times greater in the Small Office; see Table 2. Generally, this shows that the viral load has to be greater in the Big Office than in the Small Office to achieve the same

P(R) when C < 1%. This is demonstrated by Figure 1, which describes the relationship between the viral load in respiratory fluid (RNA copies per ml) in each space attributable to any number of infected people and the consequent P(R) for a susceptible occupant, if the virus emission rate is assumed to be linearly related to the viral load of the infected person.

For any viral load, L, the dose is calculated using Equation 1, and the 273 probability that it leads to an infection is calculated using Equation 2. This 274 creates a dose-response curve for both scenarios where factors that influence 275 the REI and, therefore, the dose, determine the viral loads necessary to lead 276 to a specific probability of infection. It also shows the relationship between 277 the viral load and the probability that a single infected person has that viral 278 load, P(L). The dashed vertical lines show the viral load required to give 279 a 50% probability that the dose will lead to an infection for each scenario, 280 P(R) = 50%. The area under the blue curve to the right of each vertical 281 line is the probability that the viral load of the infected person leads to 282 $P(R) \geq 50\%$. The probability is much smaller for the Big Office, which has 283 the lower REI. This probability that an infected person has a viral load that 284 leads to $P(R) \geq 50\%$ is small, suggesting that the most likely outcome is 285 $P(R) \leq 50\%$. There is great uncertainty in the magnitude of these values, 286 particularly in P(R) and in the conversion of a viral load to a virus emission 287 rate (see Section 2), but significant increases in them do not change the 288 general outcomes of the analysis. More generally, increasing the number of 289 occupants in a space while preserving the per capita volume has the effect of 290 moving the P(R) curve to the right in Figure 1 and towards the tail of the 291 P(L) curve, which reduces the likelihood that infected people in the space 292

²⁹³ have a sufficient viral load.

The P(L) distribution curve could be flattened and shifted to the left of 294 Figure 1 by reducing the viral load of the infected population; for example, 295 vaccination is shown to clear the virus from the body quicker in infected 296 vaccinated people, which at a population scale could flatten the distribution 297 of P(L) [26]. However, different variants of the SARS-CoV-2 virus could 298 increase the viral load, or the proportion of viable virions, or the infectivity 299 of virions, and move the curve to the right of Figure 1 [27, 28]. Other 300 respiratory viruses will have different distributions of the viral load but the 301 principles described here can be applied to them too. 302




Figure 1: An indication of the relationship between the viral load, L, and the consequent probability of infection, P(R), in the Big Office (green) and Small Office (red) for a susceptible occupant, and the probability of a single infected person having a viral load, P(L), (blue). Dashed vertical lines indicate the viral load required for P(R) = 50%.

303 4. Population risks

The analysis in Section 3 is underpinned by the assumption that there is 304 a single infected person in each space. When the community infection rate 305 (C) is known, Equation 3 can be used to estimate the probability that a 306 specific number of infected people are present. When C = 1%, in the Big 307 Office P(I = 0) is 61%, P(I = 1) is 31%, and P(I > 1) is 9%. For the Small 308 Office, P(I = 0) is 95%, P(I = 1) is 5%, and P(I > 1) is negligible. This 309 shows that the Big Office is 8 times more likely to have an infected person 310 present than the Small Office, although Table 1 shows that the relative risk 311 is 10 times smaller in the Big Office than the Small Office when a single 312 infected person is present. However, it is much more likely that both spaces 313 do not have an infected person present, but when they are, the most likely 314 number of infected people is 1. The mean number of transmission scenarios 315 is just over 1 in both spaces when C = 1%; see Equation 12. 316

Figure 1 shows the relationship between the probability of infection and 317 the probability of a person having a particular viral load. The viral load that 318 leads to an infection can be attributed to any number of infected people, but 319 the probability of having more than 1 infected person in a space is generally 320 small; see Equation 9. When only 1 infected person is assumed to be present, 321 Figure 1 also shows that the most probable viral loads are highly unlikely to 322 lead to an infection in either the Small Office or the Big Office. Therefore, 323 the infected person must have a significant viral load to infect susceptible 324 occupants, which is an improbable event. The infection risk for susceptible 325 occupants is lower in the Big Office than the Small Office when only 1 infected 326 person is assumed to be present. 327

Bigger spaces that preserve the *per capita* volume given in Table 1, and 328 where $N \gg 50$, have a higher probability of susceptible people, P(S), and 329 infected people, P(0 < I < N). The effect on the aerosol concentration and 330 the dose depends on the space volume per infected person, VI^{-1} , relative 331 to that of the Reference Space, the Big Office. If $V I^{-1}$ decreases, then the 332 aerosol concentration, the dose, and the probability of infection, P(R), all 333 increase. Accordingly, spaces with a high volume per occupant have a lower 334 infection risk. Here, spaces with high ceilings or low occupancy densities are 335 advantageous. 336

An increase in C also increases the probabilities of the presence of infected 337 people, P(0 < I < N), and susceptible people, P(S), in any space. This 338 increases the total viral load, the dose, D, and the probability of infection, 339 P(R). Accordingly, maintaining a low community infection rate is important. 340 It is worth noting that C may vary by region where the occupants are from, 341 or by a particular population demographic [29, 30]. Then, it is appropriate 342 to use C for that demographic, rather than using a national value. It is 343 possible to assess C by taking randomised samples from the population, such 344 as the UK Coronavirus (COVID-19) Infection Survey [31], which includes all 345 infected people at all stages of the disease. However, this survey includes 346 symptomatic people who are likely to be isolating and so the actual C is 347 likely to be lower. 348

The information in Figure 1 can be combined to determine the total proportion of people infected, *PPI*, in a space for all viral loads as a function of the probability that an individual person has a particular viral load, P(L), the probability of the risk of infection, P(R), the probability of the presence

of susceptible people P(S), and the average number of infected people, \overline{I} ; see Equations 7 and 8.

Figure 2 shows the relationship between the proportion of people infected 355 and the viral load where the area under each curve is the proportion of the 356 entire population infected for a community infection rate of C = 1%, and 357 assuming that two equal populations, one distributed evenly across a number 358 of Small Office scenarios and the other distributed evenly across a number 359 of Big Office scenarios. Figure 2 indicates that the probability of far-field 360 infection is PPI = 0.43% in the Small Office and PPI = 1.59% in the Big 361 Office, which shows that the risk is 3 to 4 times higher in the Big Office. 362 The absolute values are likely to be much smaller than those calculated here 363 because of the conservative assumptions used to estimate the viral emission 364 from viral load (see Section 2.1), so the PPI may well be $\ll 1\%$ in both spaces 365 using less conservative assumptions; see the Supplementary Materials¹. This 366 indicates that although there are benefits of subdividing for a population, 367 their magnitude needs to be considered against other factors, such as the 368 overall work environment, labour and material costs, and inadvertent changes 360 to the ventilation system and strategy. 370

A transmission ratio, TR, gives an indication of relative risk of infection where

$$TR = PPI_{comparator} / PPI_{reference}$$
(15)

Here, the TR is 0.27.

¹[add SM link]

The uncertainties in all of the values given here are significant and so it is not possible to be confident in the magnitude of the *PPI* or the *TR*, but testing the model with a range of assumptions enables an assessment of general trends; for example, how increasing occupancy and preserving *per capita* space volume and ventilation rates impact the risk of infection and how different mitigation measures, such as increasing the ventilation rate, affect the relative *PPI*. These are discussed in Section 5.





Figure 2: An indication of the relationship between the proportion of a population infected for a particular viral load when the community infection rate is C = 1%. The area under the curve represents the total proportion of people infected for the Small Office (red) and the Big Office (green).

381 5. Discussion



382 5.1. Ventilation and space volume

Figure 3: The effect of increasing the *per capita* ventilation rate, $\psi V N^{-1}$, in the Big Office on the *PPI* and the *TR* when the *per capita* ventilation rate in the Small Office is a constant 101s^{-1} per person. All values are illustrative.

The quotient of the proportion of people infected in two scenarios gives 383 a Transmission Ratio, TR, see Equation 15. Increasing the *per capita* venti-384 lation rate, $\psi V N^{-1}$, or space volume, $V N^{-1}$, in the Big Office reduces the 385 inverse of the TR. This has the effect of increasing the total removal rate, ϕ , 386 and reducing the dose and the probability of infection; see Equation 1 and 387 Figure 3. However, there is a law of diminishing returns in reducing the PPI 388 by increasing the ventilation rate because the dose is inversely proportional 389 to ϕ . Therefore, it is more important to increase the ventilation rate in a 390 poorly ventilated space than in a well ventilated space because the change in 391 the PPI is greater. 392

A similar effect is seen when increasing the *per capita* space volume in the 393 Big Office while maintaining a constant *per capita* ventilation in both spaces. 394 This is because the dose is inversely proportional to volume. Furthermore, 395 the product of the space volume and the total removal rate, ϕV , is propor-396 tional to the concentration of the virus in the air and, therefore, the infectious 397 dose. The *per capita* ventilation rate is constant in both spaces and so the 398 air change rate in the Big Office decreases as its volume increases. However, 399 this reduction is offset by the surface deposition and biological decay rates, 400 which remain constant and have a greater effect on the value of the equivalent 401 ventilation rate, ψV , as the space volume increases; see Section 2.1. 402

Equation 1 assumes a steady-state concentration of the virus has been 403 reached based on the assumption that the exposure time, T, is significant. 404 However, the time taken to reach the steady-state concentration in large 405 spaces may be significant and affects the dose over shorter exposure periods. 406 This is an example of the *reservoir effect*, the ability of indoor air to act as 407 a fresh-air reservoir and absorb the impact of contaminant emissions. The 408 greater the space volume, the greater the effect. These factors highlight the 409 benefits of increasing the *per capita* space volume. 410

411 5.2. Occupancy

Figure 4 shows the effect of increasing the number of occupants in the Big Office while maintaining both the *per capita* space volume, $V N^{-1}$, and ventilation rate, $\psi V N^{-1}$. As the number of occupants increases, the *PPI* increases at an ever diminishing rate because the magnitude of the equivalent ventilation rate, ϕV , increases at a greater rate than the probability of the mean number of infected people, \bar{I} .

However, if the volume and ventilation rate remain constant as the oc-418 cupancy increases, Figure 5 shows that the PPI and the inverse of the TR419 increase linearly with occupancy. Here, the total removal rate, ϕ , remains 420 constant but the *per capita* space volume and ventilation rate reduce. There-421 fore, the Big Office could have 14 occupants and have the same PPI as the 422 Small Office occupied by 5 people. Extrapolating to two identical popula-423 tions of 140 people split into 28 Small Offices with 5 people in each, and 10 424 Big Offices with 14 people in each, the same *PPI* can be achieved. 425

This suggests that reducing the number of occupants in a space is the most effective means of reducing the inverse of *TR* towards unity. To achieve the same goal by increasing the ventilation rate or the *per capita* space volume would require unfeasibly large increases in both.




Figure 4: The effect of increasing the occupancy in the Big Office, where the space volume per person and ventilation rate per person is fixed at 30 m^3 and 101 s^{-1} respectively, on the *PPI* (green) and *TR* (black). All values are illustrative.




Figure 5: The effect of increasing the occupancy in the Big Office where the space volume and ventilation flow rate is fixed for a designed occupancy of 50 people $(1500 \text{ m}^3 \text{ and } 500 \text{ ls}^{-1}, \text{ respectively})$, on the *PPI* and *TR*. All values are illustrative.

430 5.3. Community infection rate

Figure 6 shows that the community infection rate, C, has a significant ef-431 fect on the PPI and the TR. This is because it affects both the probability of 432 an infectious level of viral load, P(L), and the probability of having suscepti-433 ble people in a space, P(S); see Equation 10. When C > 1%, the probability 434 of transmission increases dramatically, suggesting that it strongly influences 435 the spread of the virus indoors. Figure 6 also shows that C only affects 436 the TR when the number of occupants, N, is less than the reciprocal of the 437 community infection rate in both spaces, N < 1/C. Thereafter, the TR is 438 constant irrespective of the community infection rate; see the Supplementary 439 Materials¹. 440




Figure 6: The effect of increasing the community infection rate , C, on the PPI in the Big Office (green) and the Small Office (red) and on the TR (black). All values are illustrative.

441 5.4. Overdispersion

The Monte Carlo approach described in Section 2.5 was used to interro-442 gate every scenario and estimate the number of susceptible people infected 443 when an infected person is present in the Big Office. The Monte Carlo pre-444 dictions indicate that at least one infected person was present 39% of the 445 time, confirming the value of P(S) given in Table 2 determined using Equa-446 tion 9. But, it also indicates that there was no transmission in 90% of the 447 scenarios. When a transmission does occur, the most common outcome is a 448 single transmission event; see Figure 7. This indicates that the dose inhaled 449 by all susceptible people is usually small enough not to lead to an infection. 450 At least 40 susceptible occupants are infected in the Big Office only 0.5%451 of the cases where at least one infection occurs, given the assumptions in 452 Table 1. This suggests that so called *super-spreader* events, which occur by 453

far-field airborne transmission alone, are likely to be rare; see Figure 7. This
distribution reflects the overdispersion of transmission recorded for SARSCoV-2 and, although this work only considers one transmission route, similar
relationships between the viral load and the number of transmission events
may also be true for other transmission routes [11, 32, 33, 34, 35, 36, 37].

Applying the MC approach to the Small Office shows that the overdispersion is less pronounced because there are fewer susceptible people, which limits the number of people who can be infected when an infected person has a high viral load. Here, 0.2% of all scenarios, and 25% of scenarios with at least one transmission, had 4 infections of susceptible people. In the Small Office, all 4 susceptible occupants were infected in 46% of scenarios where at least one person was infected.

There are very few epidemiological examples of high secondary COVID-19 transmission events where > 80% of occupants in a scenario are infected and this suggests that our assumptions over-estimate the viral emission rate. One reason is the assumption that all genome copies are viable virions, which is very unlikely.

Figure 7 shows that the frequency of the number of susceptible people 471 infected is highest at zero and decreases as the number of susceptible peo-472 ple infected increases. However, the frequency later increases as the number 473 of susceptible people infected approaches the number of occupants. This 474 reflects the shape of the probability of infection curve in Figure 1 where a 475 point is reached when the viral load leads to the infection of all susceptible 476 people, and a higher viral load cannot infect more people. The phenomena 477 is a function of occupancy and is less likely to occur as the number of occu-478

⁴⁷⁹ pants increases because the viral load required to infect all susceptible people
⁴⁸⁰ increases, assuming that the *per capita* space volume and ventilation rate are
⁴⁸¹ constant.




Figure 7: Uncertainty in the number of susceptible people infected in the Big Office Scenarios estimated using a Monte Carlo approach.

482 5.5. Limitations

Some limitations and uncertainties in this work have already been ad-483 dressed, particularly those concerning the viral load and the dose-response 484 relationship. However, there are a number of other aspects that increase 485 uncertainty in it. Firstly, the models assume homogenous instantly mixed 486 indoor air to simplify the estimate of a dose. This assumption is unlikely to 487 be true in some spaces, especially in large spaces where the concentrations of 488 virions in the air is likely be a function of the distance from the infected per-489 son, although it is unclear at which space volume this assumption becomes 490 less useful[38]. 491

The approach described in Section 2 only considers the far-field trans-492 mission of virus, and not near-field transmission, which is likely to be the 493 dominant route of transmission. The concentration of the virus in aerosols 494 and droplets per unit volume of air is several orders of magnitude greater 495 closer to the infected person at distances of < 2 m [3, 9]. However, it is likely 496 that the method of calculating the probability of viral load of infected people, 497 P(L), is also important for the dose received by near-field transmission and 498 should be explored further in the future. 499

The distribution of viral load of an infected person around the median will affect the probability of transmission. We apply a log-normal distribution, see Section 2, but another, such as the Weibull distribution, will affect the transmission probabilities differently.

The model also assumes a naïve population of susceptible people, and it is unclear whether a higher infective dose is required for susceptible people who have a greater immune response obtained from vaccination or a previous infection. This paper does not consider the effect of the magnitude of the dose on subsequent disease severity. However, a recent review suggests that it is highly unlikely there is a link between dose and disease severity [39].

There is uncertainty in the dose-response relationship and the proportion of people infected. In the absence of knowledge, we have assumed that the dose-response curve for SARS-CoV-1 also applies to SARS-CoV-2; see Section 2.1. The SARS-CoV-1 dose-response curve was generated from four groups of inoculated transgenic mice [23] that were genetically modified to express the human protein receptor of the SARS-CoV-1 virus. In three of the groups all mice were infected and in the fourth one-third were infected. The

dose-response curve was fitted to data from these four groups and, although 517 it is limited, it is sufficient to assume that the curve follows the exponential 518 distribution rather than the Beta-Poisson distribution. A further limitation is 519 that the response of humans to a dose of SARS-CoV-1 may vary significantly 520 from that of transgenic mice. For a further discussion, see the Supplemental 521 Material¹. There is also uncertainty in the measurement of the viral load 522 used to challenge the study, and whether or not dose curves are valid for 523 predicting low probabilities of infection at very low virus titres. Other stud-524 ies have used alternative dose-response curves for other coronaviruses, all of 525 which have similar uncertainties [21, 16]. 526

The viral load of an infected person is the number of RNA copies per ml 527 of respiratory fluid, whereas the viral emission is the amount of RNA copies 528 per unit volume of exhaled breath; see Section 2.1. It has been established 529 that the viral load of an infected person increases in time from the moment of 530 infection and is highest just before, or at, the onset of COVID-19 symptoms. 531 As COVID-19 progresses the viral load reduces, normally within the first 532 week after the onset of symptoms [40, 41]. The viral load also varies between 533 people at any stage of the infection, which increases uncertainty in it [42, 43, 43]534 44, 19, 45, 18, 30, 37]. 535

The viral load can be inferred from the *cycle threshold* values of real time reverse transcription quantitative polymerase chain reaction (RT qPCR) nasopharyngeal (NP) swabs. This method assumes a direct correlation between the viral load of a swab and the viral load of respiratory fluid [46, 12]. RT qPCR is a semi-quantitative method because it requires a number of amplification cycles to provide a positive signal of the SARS-CoV-2 genome,

which is proportional to the initial amount of viral genome in the original 542 sample. The cycle threshold is the number of polymerase chain reaction 543 cycles that are required before the chemical luminescence is read by the 544 equipment. The lower the starting amount of viral genome, the greater the 545 number of amplification cycles required. A calibrated standard curve is then 546 used to estimate the starting amount of viral genomic material. However, 547 the standard curve varies between test assays (investigative procedures) and 548 different RT qPCR thermal cyclers, the laboratory apparatus used to amplify 549 segments of RNA. This method also assumes a complete doubling of genetic 550 material after each cycle. The exponential relationship means that errors 551 in the calculation of the initial quantity of genomic material are orders of 552 magnitude higher for low cycle counts than for high cycle counts. Addition-553 ally, if genomic data is taken from NP swabs, the estimated concentration of 554 genomic material per unit volume is often related to the amount of genomic 555 material in the buffer solution² in which NP swabs are eluted and used in 556 the assay, and not necessarily to the amount in a patient's respiratory fluid. 557 The amount of genomic material added to the buffer solution is dependent 558 on both a patient's viral load and the quality of the collection of the NP 559 sample, which is highly variable. Therefore, it is not possible to determine 560 absolute values of the viral load in a patient's respiratory fluid using this 561 method. However, data collected in this way is indicative of a range of vari-562 ability, much of which is likely to be proportional to the viral load of the 563 person at the time the sample was collected. Some recent data suggests that 564

 $^{^{2}\}mathrm{a}\ buffer\ solution$ resists a change in its pH when a small quantity of acid or alkali is added to it

the viral load of NP swabs may not reflect the amount of infectious material present [19]. However, it is important to note that there are wide variations in the measured genomic material in NP swabs and that the viral load in respiratory fluid is likely to vary by several orders of magnitude.

There is clearly uncertainty in the viral load of respiratory fluid. There is also uncertainty in the viral concentration in respiratory aerosols and droplets and the distribution is currently unclear. Some studies suggest that the number of virions in small aerosols with a diameter of $< 1 \,\mu$ m is higher than would be expected given the viral concentration in the respiratory fluid [47, 48] and that for SARS-CoV-2 there may be more genomic material in the smallest aerosols [49].

There is high variability between people in the total volume of aerosols 576 generated per unit volume of exhaled breath, and it is dependent upon the 577 respiratory activity, such as talking and singing, and the respiratory capacity 578 [50, 51, 52, 53]. Coleman et al. [49] show that SARS-CoV-2 genomic material 579 is detectable in expirated aerosols from *some* COVID-19 patients, but not all 580 of them because 41% exhaled no detectable genomic material. Singing and 581 talking generally produce more genomic material than breathing, but there 582 is large variability between patients. This suggests that respiratory activities 583 that have previously been shown to increase aerosol mass also increase the 584 amount of viral genomic material emitted. However, the viral concentration 585 in aerosols cannot be determined because the study did not measure the 586 mass of aerosols generated. Coleman et al. also show that the variability in 587 the amount of genomic material measured in expirated aerosols is consistent 588 with the variability of viral loads determined using swabs and saliva [49]. 589

Similarly, Adenaive et al. [54] detected genomic material in aerosols from 590 patients infected with SARS-CoV-2 who provided a sample of exhaled air 591 when talking or singing. Genomic material was more frequently detected 592 in exhaled aerosols when the viral load of saliva or mid-turbinate swabs 593 was high; $> 10^8$ and $> 10^6$ RNA copies for mid-turbinate swabs and saliva 594 samples, respectively. Furthermore, they were able to culture viable virus 595 from < 2% of fine aerosol samples. It should be noted that one positive 596 sample was from a culture obtained from a fine aerosol sample that had an 597 amount of genomic material that was less than the detection limit of the 598 qRT PCR method that could be an artefact. Nevertheless, this provides 599 some evidence to support the epidemiological evidence that viable virus can 600 exist in exhaled aerosols. 601

Miller *et al.* suggests that around 1:1000 genome copies are likely to 602 be infectious virion [55, 12]. Adenaive et al. use mid-turbinate swabs to 603 estimate that there are around $1:10^4$ viable virus per measured genome 604 copies [54]. We make the assumption that all genome copies are viable virion, 605 which either over-estimates their infectiousness when using the Coleman et606 al. data, or is similar to the assumption of Miller et al. if the viable virion 607 emission rate is in the order of 1000 virions per hour; see Appendix Appendix 608 Α. 609

610 6. Conclusions

The number of occupants in a space can influence the risk of far-field airborne transmission that occurs at distances of > 2 m because the likelihood of having infectious and susceptible people are both associated with the number

of occupants. Therefore, mass-balance and dose-response models are applied
to determine if it is advantageous to sub-divide a large reference space into
a number of identical smaller comparator spaces to reduce the transmission
risk for an individual person and for a population of people.

The reference space is an office with a volume of $1500 \,\mathrm{m^3}$ occupied by 618 50 people over an 8 hour period, and has a ventilation rate of $10 \, \mathrm{l \, s^{-1}}$ per per-619 son. The comparator space is occupied by 5 people and preserves the oc-620 cupancy period and the *per capita* volume and ventilation rate. The dose 621 received by an individual susceptible person in the comparator Small Office, 622 when a single infected person is present, is compared to that in the reference 623 Big Office for the same circumstances to give a relative exposure index (REI) 624 with a value of 10 in the Small Office. This REI is a measure of the risk of 625 a space relative to the geometry, occupant activities, and exposure times of 626 the reference scenario and so it is not a measure of the probability of infec-627 tion. Accordingly, when a single infected person is assumed to be present, a 628 space with more occupants is less of a risk for susceptible people because the 620 equivalent ventilation rate per infected person is higher. 630

The assumption that only one infected person is present is clearly prob-631 lematic because, for a community infection rate of 1%, the most likely num-632 ber of infected people in a 50 person space is zero. A transmission event 633 can only occur when there are both one or more infected people present in 634 a space and one or more susceptible people are present. The probability of 635 a transmission event occurring increases with the number of occupants and 636 the community infection rate; for example, the Big Office is over 12 times 637 more likely to have infected people present than the Small Office. However, 638

the geometry and ventilation rate in a larger space are non-linearly related to 639 the number of infected and susceptible people and so their relationship with 640 the probability of a transmission event occurring is also non-linear. These 641 effects are evaluated by considering a large population of people. But, this 642 introduces uncertainty in factors that vary across the population, such as the 643 viral load of an infected person, defined as the number of RNA copies per ml 644 of respiratory fluid. The viral load varies over time and between people at 645 any stage of the infection. 646

By applying a distribution of viral loads across a population of infected 647 people, secondary transmissions (new infections) are found to be likely to 648 occur only when the viral load is high, although the probabilities of this 649 occurring in the Big Office and the Small Office are low. This makes it 650 hard to distinguish the route of transmission epidemiologically. Generally, 651 the viral load must be greater in the Big Office than in the Small Office to 652 achieve the same proportion of the population infected when the community 653 infection rate is $\leq 1\%$. The viable fraction is unknown but a value of unity 654 was chosen for computational ease, yet the estimated doses and infection 655 probabilities are small. Therefore, it is likely that far-field transmission is a 656 rare event that requires a set of Goldilocks conditions that are *just right*. 657

There are circumstances where the magnitude of the total viral load of the infected people is too high to affect the probability of secondary transmissions by increasing ventilation and space volume. Conversely, when the total viral load is very small, the dose so small that it is highly unlikely to lead to an infection in any space irrespective of its geometry or the number of susceptible people present. There is a law of depreciating returns for the dose and,

therefore, the probability of infection, and the ventilation rate because they are inversely related. Accordingly, it is better to focus on increasing effective ventilation rates in under-ventilated spaces rather than increasing ventilation rates above those prescribed by standards, or increasing effective ventilation rates using air cleaners, in already well-ventilated spaces.

There are significant uncertainties in the modelling assumptions and the 669 data used in the analysis and it is not possible to have confidence in the calcu-670 lated magnitudes of doses or the proportions of people infected. However, the 671 general trends and relationships described herein are less uncertain and may 672 also apply to airborne pathogens other than SARS-CoV-2 at the population 673 scale. Accordingly, it is possible to say that there are benefits of subdividing 674 a population, but their magnitudes need to be considered against other fac-675 tors, such as the overall working environment, labour and material costs, and 676 inadvertent changes to the ventilation system and strategy. However, it is 677 likely that the benefits do not outweigh the costs in existing buildings when 678 a less conservative viable fraction is used because it decreases the magnitude 670 of the benefits significantly. It is likely to be more cost-effective to consider 680 the advantages of partition when designing new resilient buildings because 681 the consequences can be considered from the beginning. 682

There are other factors that will reduce the risk of transmission in existing buildings. Local and national stakeholders can seek to maintain low community infection rates, detect infected people with high viral loads using rapid antigen tests and support to isolate them (see the Supplementary Materials³), reduce the variance and magnitude of the viral load in a population

³[add SM link]1

⁶⁸⁸ by encouraging vaccination [30]. Changes can be made to the use of exist-⁶⁸⁹ ing buildings and their services, such as reducing the occupancy density of a ⁶⁹⁰ space below the level it was designed for while preserving the magnitude of ⁶⁹¹ the ventilation rate, reducing exposure times, and ensuring compliance with ⁶⁹² ventilation standards.

693 Acknowledgements

The authors acknowledge the Engineering and Physical Sciences Research Council (EP/W002779/1) who financially supported this work. They are also grateful to Constanza Molina for her comments on this paper.

⁶⁹⁷ Appendix A. Estimating viral emission from viral load

We assume that the RNA copies per ml concentration is constant in aerosols 698 and in NP swabs and then we use the assumptions of Jones et al. [15] to con-699 vert a NP viral load into a virus emission rate. This method follows Jones et700 al. and is derived from the work of Morawskwa et al. who determine vol-701 ume distribution aerosols for different respiratory activities, and is similar 702 to that used by Lelieveld *et al.* [15, 17, 53]. Table A.3 shows the estimated 703 virus emission rate for different respiratory activities when the viral load 704 is 10⁷ RNA copies per ml. For comparison, median measured values of virus 705 emission in aerosols from Coleman *et al.* are given. These values were mea-706 sured by collecting RNA copies from COVID-19 patients, where the median 707 cycle threshold, required to process diagnostic samples, was 16. [49]. 708 709

	Estimated	Measured median
	$\rm RNA copies h^{-1}$	${\rm RNA}{\rm copies}{\rm h}^{-1}$
Breathing	203	127
Voiced counting (talking)	967	1912
Vocalisation (singing)	6198	2856
Breathing:talking 25:75	394	573*

Table A.3: Estimated emission rates from an infected person with a viral load of 10^7 RNA copies per ml compared to measured emission rates from patients with a median cycle threshold of 16 [49]

*calculated using measured values for breathing and talking.

Additionally, unpublished work by Adenaiye *et al.* measured viral genome in patients infected by the SARS-CoV-2 alpha variant, who were breathing and talking, in coarse (> 5 μ m) and fine (\leq 5 μ m) aerosols with a total geometric mean of 1440 RNA copies h⁻¹ and a maximum of 3×10⁵ RNA copies h⁻¹ [54]. These are greater than the estimated values given in Table A.3, but the viral load, measured by genome copies from mid-turbinate swabs, was generally orders of magnitude higher than 10⁷ RNA copies per ml.

In Section 4, the inhaled dose is calculated for all possible viral loads. 717 Here, it should be noted that the calculated RNA copies emission rate is as-718 sumed to be linearly related to the viral load of respiratory fluids, so that 719 a viral load of 10⁸ RNA copies per ml has a ten-fold greater emission rate. 720 For comparison, a virus emission rate of 394 RNA copies h^{-1} (assumed for a 721 viral load of 10⁷ RNA copies per ml) leads to an individual doses of around 722 2.2 RNA copies and 0.2 RNA copies for the Small Office and Big Office sce-723 narios, respectively. 724

- The calculated emission rate of viral genome for a viral load of 10^7 RNA copies per ml
- ⁷²⁶ is a reasonable fit to the Coleman *et al.* and Adenaiye *et al.* data. For further
- ⁷²⁷ details see the Supplementary Materials⁴.

 $^{^{4}}$ [add SM link]1

728 References

- [1] C. C. Wang, K. A. Prather, J. Sznitman, J. L. Jimenez, S. S. Lakdawala,
 Z. Tufekci, L. C. Marr, Airborne transmission of respiratory viruses, Sci-
- ence 373 (6558) (2021) eabd9149. doi:10.1126/science.abd9149.
- ⁷³² URL https://www.sciencemag.org/lookup/doi/10.1126/science.
 ⁷³³ abd9149
- [2] L. Bourouiba, Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19,
 JAMA Journal of the American Medical Association 323 (18) (2020)
 1837–1838. doi:10.1001/jama.2020.4756.
- [3] G. Cortellessa, L. Stabile, F. Arpino, D. Faleiros, W. van den Bos,
 L. Morawska, G. Buonanno, Close proximity risk assessment for SARSCoV-2 infection, Science of The Total Environment 794 (2021) 148749.
 doi:10.1016/j.scitotenv.2021.148749.
- ⁷⁴² URL https://doi.org/10.1016/j.scitotenv.2021.148749
- [4] Q. Yang, T. K. Saldi, P. K. Gonzales, E. Lasda, C. J. Decker, K. L. 743 Tat, M. R. Fink, C. R. Hager, J. C. Davis, C. D. Ozeroff, D. Muhlrad, 744 S. K. Clark, W. T. Fattor, N. R. Meyerson, C. L. Paige, A. R. Gilchrist, 745 A. Barbachano-Guerrero, E. R. Worden-Sapper, S. S. Wu, G. R. Bris-746 son, M. B. McQueen, R. D. Dowell, L. Leinwand, R. Parker, S. L. 747 Sawyer, Just 2 percent of sars-cov-2 positive individuals carry 90 per-748 cent of the virus circulating in communities, Proceedings of the National 749 Academy of Sciences 118 (21) (2021) e2104547118. doi:10.1073/pnas. 750

- 751 2104547118.
- ⁷⁵² URL http://www.pnas.org/lookup/doi/10.1073/pnas.2104547118
- [5] P. Dabisch, M. Schuit, A. Herzog, K. Beck, S. Wood, M. Krause,
 D. Miller, W. Weaver, D. Freeburger, I. Hooper, B. Green, G. Williams,
 B. Holland, J. Bohannon, V. Wahl, J. Yolitz, M. Hevey, S. RatnesarShumate, The influence of temperature, humidity, and simulated sunlight on the infectivity of SARS-CoV-2 in aerosols, Aerosol Science
 and Technology 55 (2) (2021) 142–153. doi:10.1080/02786826.2020.
 1829536.
- URL https://www.tandfonline.com/doi/full/10.1080/02786826.
 2020.1829536
- [6] Z. Liu, Q. Guo, L. Zou, H. Zhang, M. Zhang, F. Ouyang, J. Su, W. Su,
 J. Xu, H. Lin, J. Sun, J. Peng, H. Jiang, P. Zhou, H. Zhen, T. Liu,
 R. Che, H. Zeng, Z. Zheng, J. Yu, L. Yi, J. Wu, J. Chen, H. Zhong,
 X. Deng, M. Kang, O. G. Pybus, M. Hall, K. A. Lythgoe, Viral infection
 and transmission in a large well- traced outbreak caused by the Delta
 SARS-CoV-2 variant, Virological.org (2021).
- URL https://virological.org/t/viral-infection-and-transmission-in-a-large-wel
 769 724
- 770 [7] T. C. Bulfone, M. Malekinejad, G. W. Rutherford, N. Razani, Out-
- door Transmission of SARS-CoV-2 and Other Respiratory Viruses: A
- 572 Systematic Review, The Journal of infectious diseases 223 (4) (2021)
- ⁷⁷³ 550-561. doi:10.1093/infdis/jiaa742.
- [8] M. Weed, A. Foad, Rapid scoping review of evidence of outdoor trans-

- mission of COVID-19, (pre-print) (2020). doi:10.1101/2020.09.04.
 20188417.
- [9] N. Zhang, W. Chen, P. T. Chan, H. L. Yen, J. W. T. Tang, Y. Li, Close
 contact behavior in indoor environment and transmission of respiratory
 infection, Indoor Air 30 (4) (2020) 645–661. doi:10.1111/ina.12673.
- [10] SAGE, SARS-COV-2 Transmission routes and environments, Tech.
 Rep. October, SAGE, UK (2020).
- URL https://assets.publishing.service.gov.uk/government/
- uploads/system/uploads/attachment_data/file/933225/S0824_
- 784 SARS-CoV-2_Transmission_routes_and_environments.pdf
- [11] K. Escandón, A. L. Rasmussen, I. I. Bogoch, E. J. Murray, K. Es-785 candón, S. V. Popescu, J. Kindrachuk, COVID-19 false dichotomies 786 and a comprehensive review of the evidence regarding public health, 787 COVID-19 symptomatology, SARS-CoV-2 transmission, mask wear-788 ing, and reinfection, BMC Infectious Diseases 21 (1) (2021) 710. 789 arXiv:arXiv:1011.1669v3, doi:10.1186/s12879-021-06357-4. 790 URL https://osf.io/k2d84/https://bmcinfectdis. 791 biomedcentral.com/articles/10.1186/s12879-021-06357-4 792

[12] S. L. Miller, W. W. Nazaroff, J. L. Jimenez, A. Boerstra, S. J. Dancer,
J. Kurnitski, L. C. Marr, L. Morawska, C. Noakes, Transmission of
SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley
Chorale superspreading event, Indoor Air in press (2020). doi:doi.
org/10.1111/ina.12751.

- [13] D. Hijnen, A. Marzano, K. Eyerich, C. GeurtsvanKessel, A. GiménezArnau, P. Joly, C. Vestergaard, M. Sticherling, E. Schmidt, Sars-cov-2
 transmission from presymptomatic meeting attendee, germany., Emerging infectious diseases 26 (8) (2020). doi:10.3201/eid2608.201235.
- [14] L. M. Groves, L. Usagawa, J. Elm, E. Low, A. Manuzak, J. Quint, K. E.
 Center, A. M. Buff, S. K. Kemble, Community Transmission of SARSCoV-2 at Three Fitness Facilities Hawaii, June–July 2020, MMWR
 Surveillance Summaries 70 (9) (2021) 316–320. doi:10.15585/mmwr.
 mm7009e1.
- [15] B. Jones, P. Sharpe, C. Iddon, E. A. Hathway, C. J. Noakes, S. Fitzgerald, Modelling uncertainty in the relative risk of exposure to the SARSCoV-2 virus by airborne aerosol transmission in well mixed indoor air,
 Building and Environment 191 (October 2020) (2021) 107617. doi:
 10.1016/j.buildenv.2021.107617.
- ⁸¹² URL https://doi.org/10.1016/j.buildenv.2021.107617
- [16] H. Parhizkar, K. G. Van Den Wymelenberg, C. N. Haas, R. L. Corsi, A
 Quantitative Risk Estimation Platform for Indoor Aerosol Transmission
 of COVID-19, Risk Analysis 0 (0) (2021). doi:10.1111/risa.13844.
- [17] J. Lelieveld, F. Helleis, S. Borrmann, Y. Cheng, F. Drewnick, G. Haug,
 T. Klimach, J. Sciare, H. Su, U. Pöschl, Model calculations of aerosol
 transmission and infection risk of covid-19 in indoor environments, International Journal of Environmental Research and Public Health 17 (21)
 (2020) 1–18. doi:10.3390/ijerph17218114.

821	[18]	P. Z. Chen, N. Bobrovitz, Z. Premji, M. Koopmans, D. N. Fisman, F. X.
822		Gu, Heterogeneity in transmissibility and shedding SARS-CoV-2 via
823		droplets and aerosols, eLife 10 (2021) 1–32. doi:10.7554/elife.65774.
824	[19]	R. Ke, P. P. Martinez, R. L. Smith, L. L. Gibson, A. Mirza, M. Conte,
825		N. Gallagher, C. H. Luo, J. Jarrett, A. Conte, M. Farjo, K. K. O.
826		Walden, G. Rendon, C. J. Fields, R. Fredrickson, D. C. Edmonson,
827		M. E. Baughman, K. K. Chiu, J. Yedetore, J. Quicksall, A. N.
828		Owens, J. Broach, Daily sampling of early SARS-CoV-2 infection
829		reveals substantial heterogeneity in infectiousness, (pre-print) (2021).
830		doi:https://doi.org/10.1101/2021.07.12.21260208.
831		URL https://www.medrxiv.org/content/10.1101/2021.07.12.
832		21260208v1

- [20] P. Z. Chen, N. Bobrovitz, Z. Premji, M. Koopmans, D. N. Fisman, F. X. 833 Gu, Sars-cov-2 shedding dynamics across the respiratory tract, sex, and 834 disease severity for adult and pediatric covid-19, eLife 10 (2021) e70458. 835 doi:10.7554/eLife.70458. 836
- URL https://doi.org/10.7554/eLife.70458 837

- [21] T. Watanabe, T. A. Bartrand, M. H. Weir, T. Omura, C. N. Haas, 838 Development of a dose-response model for sars coronavirus. risk analysis: 839 an official publication of the society for risk analysis, Risk Anal 30 (7) 840 (2010) 1129-1138. doi:10.1111/j.1539-6924.2010.01427.x. 841
- [22] X. Zhang, J. Wang, Dose-response Relation Deduced for Coronaviruses 842 From Coronavirus Disease 2019, Severe Acute Respiratory Syndrome, 843 and Middle East Respiratory Syndrome: Meta-analysis Results and its 844

845		Application for Infection Risk Assessment of Aerosol Transmission, Clin-
846		ical Infectious Diseases 73 (1) (2020) 1–5. doi:10.1093/cid/ciaa1675.
847	[23]	M. L. DeDiego, L. Pewe, E. Alvarez, M. T. Rejas, S. Perlman, L. En-
848		juanes, Pathogenicity of severe acute respiratory coronavirus deletion
849		mutants in hace-2 transgenic mice, Virology 376 (2) (2008) 379–389.
850		doi:https://doi.org/10.1016/j.virol.2008.03.005.
851		URL https://www.sciencedirect.com/science/article/pii/
852		S004268220800175X
853	[24]	SAGE, Emg: Role of ventilation in controlling sars-cov-2 transmission,
854		Tech. Rep. September, SAGE, UK (2020).
855		URL https://www.gov.uk/government/publications/
856		emg-role-of-ventilation-in-controlling-sars-cov-2-transmission-30-september-2
857	[25]	C. Molina, C. Iddon, P. Sharpe, B. Jones, CIBSE relative exposure
858		index calculator (2021).
859		URL https://www.cibse.org/coronavirus-covid-19/
860		emerging-from-lockdown#5
861	[26]	P. Y. Chia, S. W. X. Ong, C. J. Chiew, L. W. Ang, JM. Chavatte,
862		TM. Mak, L. Cui, S. Kalimuddin, W. N. Chia, C. W. Tan, L. Y. A.
863		Chai, S. Y. Tan, S. Zheng, R. T. P. Lin, L. Wang, YS. Leo, V. J. Lee,
864		D. C. Lye, B. E. Young, Virological and serological kinetics of sars-cov-
865		2 delta variant vaccine-breakthrough infections: a multi-center cohort
866		study, (pre-print) (2021).
867	[27]	A. Singanayagam, S. Hakki, J. Dunning, K. J. Madon, M. A. Crone,

868		A. Koycheva, N. Derqui-Fernandez, J. L. Barnett, M. G. Whitfield,
869		R. Varro, A. Charlett, R. Kundu, J. Fenn, J. Cutajar, V. Quinn,
		E. Conibear, W. Barclay, P. S. Freemont, G. P. Taylor, S. Ahmad,
870		
871		M. Zambon, N. M. Ferguson, A. Lalvani, A. Badhan, S. Dustan,
872		C. Tejpal, A. V. Ketkar, J. S. Narean, S. Hammett, E. McDermott,
873		T. Pillay, H. Houston, C. Luca, J. Samuel, S. Bremang, S. Evetts,
874		J. Poh, C. Anderson, D. Jackson, S. Miah, J. Ellis, A. Lackenby,
875		Community transmission and viral load kinetics of the SARS-CoV-2
876		delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in
877		the UK: a prospective, longitudinal, cohort study, The Lancet Infectious
878		Diseases 3099 (21) (oct 2021). doi:10.1016/S1473-3099(21)00648-4.
879		URL https://linkinghub.elsevier.com/retrieve/pii/
880		S1473309921006484
881	[28]	D. W. Eyre, D. Taylor, M. Purver, D. Chapman, T. Fowler, K. Pouwels,
882		A. S. Walker, T. E. A. Peto, The impact of SARS-CoV-2 vaccination
883		on Alpha and Delta variant transmission, (pre-print) (2021).
884		URL http://medrxiv.org/content/early/2021/09/29/2021.09.
885		28.21264260.abstract
	[]	
886	[29]	M. Cevik, S. D. Baral, Networks of SARS-CoV-2 transmission., Science
887		(New York, N.Y.) 373 (6551) (2021) 162-163. doi:10.1126/science.
888		abg0842.
889		URL http://www.ncbi.nlm.nih.gov/pubmed/34244400
	[30]	I V W Loo S Rozmanowski M Dang A Charlott C Anderson
890	[30]	L. Y. W. Lee, S. Rozmanowski, M. Pang, A. Charlett, C. Anderson,
891		G. J. Hughes, M. Barnard, L. Peto, R. Vipond, A. Sienkiewicz,

S. Hopkins, J. Bell, D. W. Crook, N. Gent, A. S. Walker, T. E. A. 892 Peto, D. W. Eyre, Severe Acute Respiratory Syndrome Coronavirus 893 2 (SARS-CoV-2) Infectivity by Viral Load, S Gene Variants and 894 Demographic Factors, and the Utility of Lateral Flow Devices to 895 Prevent Transmission, Clinical Infectious Diseases 6 (2021) 1–32. 896 doi:10.1093/cid/ciab421. 897 URL https://academic.oup.com/cid/advance-article/doi/10. 898 1093/cid/ciab421/6273394 899 [31] ONS, ONS Coronavirus (COVID-19)Infection Survey, 900

https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsande
 (2021).

[32] Q. Bi, Y. Wu, S. Mei, C. Ye, X. Zou, Z. Zhang, X. Liu, L. Wei,
S. A. Truelove, T. Zhang, W. Gao, C. Cheng, X. Tang, X. Wu,
Y. Wu, B. Sun, S. Huang, Y. Sun, J. Zhang, T. Ma, J. Lessler,
T. Feng, Epidemiology and transmission of COVID-19 in 391 cases
and 1286 of their close contacts in Shenzhen, China: a retrospective
cohort study, The Lancet Infectious Diseases 20 (8) (2020) 911–919.
doi:10.1016/S1473-3099(20)30287-5.

[33] J. E. Lemieux, K. J. Siddle, B. M. Shaw, C. Loreth, S. F. Schaffner,
A. Gladden-Young, G. Adams, T. Fink, C. H. Tomkins-Tinch, L. A.
Krasilnikova, K. C. DeRuff, M. Rudy, M. R. Bauer, K. A. Lagerborg,
E. Normandin, S. B. Chapman, S. K. Reilly, M. N. Anahtar, A. E.
Lin, A. Carter, C. Myhrvold, M. E. Kemball, S. Chaluvadi, C. Cusick,
K. Flowers, A. Neumann, F. Cerrato, M. Farhat, D. Slater, J. B. Harris,

916		J. A. Branda, D. Hooper, J. M. Gaeta, T. P. Baggett, J. O'Connell,
917		A. Gnirke, T. D. Lieberman, A. Philippakis, M. Burns, C. M. Brown,
918		J. Luban, E. T. Ryan, S. E. Turbett, R. C. LaRocque, W. P. Hanage,
919		G. R. Gallagher, L. C. Madoff, S. Smole, V. M. Pierce, E. Rosenberg,
920		P. C. Sabeti, D. J. Park, B. L. MacInnis, Phylogenetic analysis of SARS-
921		CoV-2 in Boston highlights the impact of superspreading events, Science
922		371 (6529) (2021). doi:10.1126/science.abe3261.
923	[34]	D. Miller, M. A. Martin, N. Harel, O. Tirosh, T. Kustin, M. Meir,
924		N. Sorek, S. Gefen-Halevi, S. Amit, O. Vorontsov, A. Shaag, D. Wolf,
925		A. Peretz, Y. Shemer-Avni, D. Roif-Kaminsky, N. M. Kopelman,
926		A. Huppert, K. Koelle, A. Stern, Full genome viral sequences inform
927		patterns of SARS-CoV-2 spread into and within Israel, Nature Commu-
928		nications 11 (1) (2020). doi:10.1038/s41467-020-19248-0.
929		URL http://dx.doi.org/10.1038/s41467-020-19248-0
930	[35]	J. Riou, C. L. Althaus, Pattern of early human-to-human trans-
931		mission of Wuhan 2019 novel coronavirus (2019-nCoV), Decem-
932		ber 2019 to January 2020, Eurosurveillance 25 (4) (2020) 1–5.
933		doi:10.2807/1560-7917.ES.2020.25.4.2000058.
934		URL http://dx.doi.org/10.2807/1560-7917.ES.2020.25.4.
935		2000058
936	[36]	S. Chaudhuri, P. Kasibhatla, A. Mukherjee, W. Pan, G. Morrison,

- S. Mishra, V. K. Murty, Analysis of overdispersion in airborne transmission of Covid-19, (pre-print) (2021).
- 939 URL https://doi.org/10.1101/2021.09.28.21263801

- [37] A. Goyal, D. B. Reeves, E. F. Cardozo-Ojeda, J. T. Schiffer, B. T.
 Mayer, Viral load and contact heterogeneity predict sars-cov-2 transmission and super-spreading events, eLife 10 (2021) 1–63. doi:10.7554/
 eLife.63537.
- [38] G. N. Sze To, C. Y. H. Chao, Review and comparison between the
 wells-riley and dose-response approaches to risk assessment of infectious
 respiratory diseases, Indoor air 20 (1) (2010) 2–16. doi:10.1111/j.
 1600-0668.2009.00621.x.
- [39] L. M. Brosseau, K. Escandón, A. K. Ulrich, A. L. Rasmussen, C. J. Roy,
 G. J. Bix, S. V. Popescu, K. Moore, M. T. Osterholm, SARS-CoV-2
 Dose, Infection, and Disease Outcomes for COVID-19 A Review, Clinical Infectious Diseases 54 (2021) 1–54. doi:10.1093/cid/ciab903.
- ⁹⁵² URL https://academic.oup.com/cid/advance-article/doi/10.
 ⁹⁵³ 1093/cid/ciab903/6397523
- [40] M. Cevik, K. Kuppalli, J. Kindrachuk, M. Peiris, Virology, transmission,
 and pathogenesis of SARS-CoV-2, The BMJ 371 (2020) 1–6. doi:10.
 1136/bmj.m3862.
- [41] M. Cevik, M. Tate, O. Lloyd, A. E. Maraolo, J. Schafers, A. Ho,
 SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and
 meta-analysis, The Lancet Microbe 2 (1) (2021) e13–e22. doi:10.1016/
 S2666-5247(20)30172-5.
- ⁹⁶² URL http://dx.doi.org/10.1016/S2666-5247(20)30172-5

- ⁹⁶³ [42] Y. Pan, D. Zhang, P. Yang, L. L. Poon, Q. Wang, Viral load of SARS⁹⁶⁴ CoV-2 in clinical samples, The Lancet Infectious Diseases 20 (4) (2020)
- 965 411-412. doi:10.1016/S1473-3099(20)30113-4.
- ⁹⁶⁶ URL http://dx.doi.org/10.1016/S1473-3099(20)30113-4
- [43] S. Karimzadeh, R. Bhopal, H. Nguyen Tien, Review of infective
 dose, routes of transmission and outcome of COVID-19 caused
 by the SARS-COV-2: comparison with other respiratory viruses–
 CORRIGENDUM, Epidemiology and Infection 149 (2021) e116.
 doi:10.1017/S0950268821001084.
- URL https://www.cambridge.org/core/product/identifier/
 S0950268821001084/type/journal_article
- [44] R. Challen, E. Brooks-Pollock, J. M. Read, L. Dyson, K. Tsaneva-Atanasova, L. Danon, Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort study, The BMJ 372 (2021) 1–10. doi:10.1136/bmj.n579.
- [45] A. S. Walker, E. Pritchard, T. House, J. V. Robotham, P. J. Birrell,
 I. Bell, J. Bell, J. Newton, J. Farrar, I. Diamond, R. Studley, J. Hay,
 K.-D. Vihta, T. E. Peto, N. Stoesser, P. C. Matthews, D. W. Eyre,
 K. Pouwels, Ct threshold values, a proxy for viral load in community
 SARS-CoV-2 cases, demonstrate wide variation across populations and
 over time, eLife 10 (jul 2021). doi:10.7554/eLife.64683.
- URL https://elifesciences.org/articles/64683
- ⁹⁸⁵ [46] G. Buonanno, L. Stabile, L. Morawska, Estimation of airborne viral
 ⁹⁸⁶ emission: Quanta emission rate of SARS-CoV-2 for infection risk as-

- sessment, Environment International 141 (May) (2020) 105794. doi:
 10.1016/j.envint.2020.105794.
- [47] D. K. Milton, M. P. Fabian, B. J. Cowling, M. L. Grantham, J. J.
 McDevitt, Influenza Virus Aerosols in Human Exhaled Breath: Particle
 Size, Culturability, and Effect of Surgical Masks, PLoS Pathogens 9 (3)
 (2013). doi:10.1371/journal.ppat.1003205.
- [48] P. Fabian, J. J. McDevitt, W. H. DeHaan, R. O. Fung, B. J. Cowling,
 K. H. Chan, G. M. Leung, D. K. Milton, Influenza virus in human
 exhaled breath: An observational study, PLoS ONE 3 (7) (2008) 5–10.
 doi:10.1371/journal.pone.0002691.
- [49] K. K. Coleman, D. J. W. Tay, K. S. Tan, S. W. X. Ong, T. S. Than,
 M. H. Koh, Y. Q. Chin, H. Nasir, T. M. Mak, J. J. H. Chu, D. K. Milton,
 V. T. K. Chow, P. A. Tambyah, M. Chen, K. W. Tham, Viral Load of
 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in
 Respiratory Aerosols Emitted by Patients With Coronavirus Disease
 2019 (COVID-19) While Breathing, Talking, and Singing, Clinical
 Infectious Diseases 2 (Xx) (2021) 1–7. doi:10.1093/cid/ciab691.
- URL https://academic.oup.com/cid/advance-article/doi/10.
 1005 1093/cid/ciab691/6343417
- [50] F. K. Gregson, N. A. Watson, C. M. Orton, A. E. Haddrell, L. P. McCarthy, T. J. Finnie, N. Gent, G. C. Donaldson, P. L. Shah, J. D.
 Calder, B. R. Bzdek, D. Costello, J. P. Reid, Comparing aerosol concentrations and particle size distributions generated by singing, speaking
 and breathing, Aerosol Science and Technology 55 (6) (2021) 681–691.

doi:10.1080/02786826.2021.1883544.

- ¹⁰¹² URL https://doi.org/10.1080/02786826.2021.1883544
- [51] G. R. Johnson, L. Morawska, The mechanism of breath aerosol formation, Journal of Aerosol Medicine and Pulmonary Drug Delivery 22 (3)
 (2009) 229–237. doi:10.1089/jamp.2008.0720.
- [52] G. R. Johnson, L. Morawska, Z. D. Ristovski, M. Hargreaves,
 K. Mengersen, C. Y. Chao, M. P. Wan, Y. Li, X. Xie, D. Katoshevski, S. Corbett, Modality of human expired aerosol size distributions, Journal of Aerosol Science 42 (12) (2011) 839–851. doi:
 10.1016/j.jaerosci.2011.07.009.
- [53] L. Morawska, G. R. Johnson, Z. D. Ristovski, M. Hargreaves,
 K. Mengersen, S. Corbett, C. Y. Chao, Y. Li, D. Katoshevski, Size distribution and sites of origin of droplets expelled from the human respiratory tract during expiratory activities, Journal of Aerosol Science 40 (3) (2009) 256–269. doi:10.1016/j.jaerosci.2008.11.002.
- [54] O. O. Adenaiye, J. Lai, P. J. B. de Mesquita, F. Hong, S. Youssefi,
 J. German, S.-H. S. Tai, B. Albert, M. Schanz, S. Weston, J. Hang,
 C. Fung, H. K. Chung, K. K. Coleman, N. Sapoval, T. Treangen,
 I. M. Berry, K. Mullins, M. Frieman, T. Ma, D. K. Milton, Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During
 Early Mild Infection, (pre-print) (2021). arXiv:2021.08.13.21261989,
 doi:https://doi.org/10.1101/2021.08.13.21261989.
- ¹⁰³³ URL https://doi.org/10.1101/2021.08.13.21261989

1034	[55] V. M. Corman, I. Eckerle, T. Bleicker, A. Zaki, O. Landt, M. Eschbach-
1035	Bludau, S. van Boheemen, R. Gopal, M. Ballhause, T. M. Bestebroer,
1036	D. Muth, M. A. Müller, J. F. Drexler, M. Zambon, A. D. Osterhaus,
1037	R. M. Fouchier, C. Drosten, Detection of a novel human coronavirus by
1038	real-time reverse-transcription polymerase chain reaction, Eurosurveil-
1039	lance 17 (39) (2012) 1-6. doi:10.2807/ese.17.39.20285-en.
1040	URL http://dx.doi.org/10.2807/ese.17.39.20285-en